Tyrosine kinase inhibitor as adjuvant treatment of renal cell carcinoma: 1 versus 3

被引：0
|
作者：
Penel, Nicolas [1 ]
机构：
[1] Ctr Oscar Lambret, Dept Cancerol Gen, 3 Rue F Combemale, F-59020 Lille, France
来源：
BULLETIN DU CANCER | 2017年 / 104卷 / 09期
关键词：
Renal cell carcinoma; Adjuvant; Pazopanib; NEPHRECTOMY;
D O I：
10.1016/j.bulcan.2017.06.015
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：705 / 706
页数：2
相关论文
共 50 条
  • [21] Developments in the use of tyrosine kinase inhibitors in the treatment of renal cell carcinoma
    Reed, Jarred P.
    Posadas, Edwin M.
    Figlin, Robert A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (03) : 259 - 271
  • [22] Tyrosine kinase inhibitors in renal cell carcinoma
    Potti, A
    George, DJ
    CLINICAL CANCER RESEARCH, 2004, 10 (18) : 6371S - 6376S
  • [23] Ongoing Screening and Treatment to Potentially Reduce Tyrosine Kinase Inhibitor-Related Fatigue in Renal Cell Carcinoma
    Anand, Deepa
    Escalante, Carmen P.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2015, 50 (01) : 108 - 117
  • [24] Metastatic renal cell carcinoma regains sensitivity to tyrosine kinase inhibitor after nivolumab treatment: A case report
    Azuma, Takeshi
    Sugihara, Tohru
    Honda, Sachi
    Yoshizaki, Uran
    Nimi, Fusako
    Tsuru, Ibuki
    Kume, Haruki
    ONCOLOGY LETTERS, 2019, 17 (04) : 4011 - 4015
  • [25] Tyrosine kinase inhibitor treatment for renal cell carcinoma with inferior vena cava tumour thrombus: a quantitative summary
    Klatte, Tobias
    Welsh, Sarah J. J.
    Riddick, Antony C. P.
    Karam, Jose A.
    Stewart, Grant D. D.
    BJU INTERNATIONAL, 2023, 131 (05) : 566 - 568
  • [26] Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?
    Mário Fontes-Sousa
    Helena Magalhães
    Alicia Oliveira
    Filipa Carneiro
    Filipa Palma dos Reis
    Pedro Silvestre Madeira
    Sara Meireles
    Advances in Therapy, 2022, 39 : 1107 - 1125
  • [27] Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?
    Fontes-Sousa, Mario
    Magalhaes, Helena
    Oliveira, Alicia
    Carneiro, Filipa
    dos Reis, Filipa Palma
    Madeira, Pedro Silvestre
    Meireles, Sara
    ADVANCES IN THERAPY, 2022, 39 (03) : 1107 - 1125
  • [28] Novel role of a tyrosine kinase inhibitor by reversion of immune suppression in renal cell carcinoma
    Seliger, B.
    Mueller, A.
    Giersberg, Corinna
    Handke, Diana
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Cryoablation following neoadjuvant tyrosine kinase inhibitor as treatment of a T1a renal clear cell carcinoma in a patient with a solitary kidney
    Diederichsen, Marie Zoega
    Weile, Kathrine Synne
    Christiansen, Cecilie Bekker
    Pietersen, Pia Iben
    BMJ CASE REPORTS, 2023, 16 (08)
  • [30] Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present) reply
    Kourie, Hampig R.
    Bakouny, Ziad
    Haddad, Fady G. H.
    Eid, Roland
    Kattan, Joseph
    FUTURE ONCOLOGY, 2018, 14 (22) : 2225 - 2227
12345